Edwards Lifesciences Corporation EW

86.29 0.56 0.65% as of 25 Sep
Market cap
$49.4B
P/E
49.6×
Indexes indicate stock being part of an index,
Growth Flags show if company had growth for consecutive years

Edwards Lifesciences Corporation (EW) Debt to equity

Edwards Lifesciences Corporation's debt to equity at the end of the quarter to 30 June 2026 was 0.1×, down 0.0× from fiscal 2025 (0.1×). Over the past ten years it has ranged from 0.1× (fiscal 2025) to 0.4× (fiscal 2017) — the current reading is the lowest in ten years. That is below the Medical Devices industry median of 0.1× and above the Healthcare sector median of 0.0×.

Debt to equity, annual

Annual

Period Debt to equity Change
FY2025 0.1× (2.53%)
FY2024 0.1× (33.11%)
FY2023 0.1× (17.16%)
FY2022 0.1× 0.66%
FY2021 0.1× (21.69%)
FY2020 0.1× (9.09%)
FY2019 0.1× (20.89%)
FY2018 0.2× (46.06%)
FY2017 0.4× 11.66%
FY2016 0.3× 31.66%

Quarterly

Period Debt to equity Change
Jun 2026 0.1× (3.79%)
Mar 2026 0.1× 0.17%
Dec 2025 0.1× (1.19%)
Sep 2025 0.1× 3.90%
42 more quarters

Against its own ten years

Low 0.1× High 0.4×
Ten-year median 0.1×
Current reading's percentile 9

Debt to equity against peers

Company Debt to equity
EW Edwards Lifesciences Corporation 0.1×
STE STERIS plc compare 0.3×
DXCM DexCom, Inc. compare 0.5×
BSX Boston Scientific Corporation compare 0.5×
PHG Koninklijke Philips N.V. compare 0.6×
MDT Medtronic PLC compare 0.6×
ZBH Zimmer Biomet Holdings, Inc. compare 0.6×
SYK Stryker Corporation compare 0.6×
GEHC GE HealthCare Technologies Inc. compare 1.0×
Medical Devices industry median 0.1×
Healthcare sector median 0.0×
Market median 0.2×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on EW